Page URL:

Genetic factors important in survival after breast cancer, study shows

9 August 2010
Appeared in BioNews 570

A UK study has revealed that breast cancer patients who have the POLQ gene are eight times more likely to suffer from recurrence after treatment compared to patients who do not carry the gene.

A lack of the gene DNA polymerase theta (POLQ) has previously been shown to make tumour cells more sensitive to radiotherapy.

Scientists based at the Cancer Research UK/MRC Gray Institute for Radiation Oncology and Biology at Oxford University investigated whether 279 women with breast cancer who over-expressed POLQ had worse outcomes than women who did not. The team reported that excessive POLQ was associated with an 8.1 times higher risk of poor survival, which was independent of other clinical features of the women's cancer including how big their tumours were and how old they were.

'This is important research which provides evidence that POLQ may be a very appealing target for drug development', said Professor Gillies McKenna, director of the Institute.

'As POLQ is not switched on by most healthy tissues it is possible that if drugs could be developed to block this gene, they would make tumours more responsive to treatments such as radiotherapy and chemotherapy, but not increase the side effects caused to healthy cells'.

The researchers are unsure as to why POLQ is linked to poor survival, but they suggest that it could cause tumour cells to be resistant to treatments including radiotherapy, which are frequently used to treat breast cancer patients with early stage disease. POLQ could also induce tumour cells to behave more aggressively than cancers that do not express the gene.

'Drugs that block POLQ may be able to reverse the very poor survival associated with over production of this gene', added Professor McKenna.

In 2007, almost 45,700 women in the UK were diagnosed with breast cancer, according to figures from Cancer Research UK.

Dr Lesley Walker, science information director at the charity said: ‘Fundamental scientific research like this to examine the genetic causes for breast cancer provides us with the foundations to develop new exciting drugs to beat the disease and increase survival in the future'.

Blocking gene boosts cancer killing radiotherapy
BBC News |  2 April 2010
Gene target may block breast cancer recurrence and boost survival
Cancer Research UK |  5 August 2010
Overexpression of POLQ Confers a Poor Prognosis in Early Breast Cancer Patients
Oncotarget |  9 July 2010
16 May 2011 - by Dr Kimberley Bryon-Dodd 
Screening for breast and prostate cancer based on genetic risk factors as well as age could reduce the number of people screened without a significant reduction in the number of cancers detected, a new study suggests....
16 May 2011 - by Dr Jay Stone 
US scientists have designed a genetic test which could predict how a patient with breast cancer responds to chemotherapy. Researchers say the test, which works for those with certain newly diagnosed forms of cancer, could help women avoid unnecessary chemotherapy....
7 March 2011 - by Dr Jay Stone 
Scientists at Queen's University, Belfast, have developed a new targeted gene therapy for the treatment of breast cancer....
13 September 2010 - by Chris Chatterton and Jay Stone 
A group of international researchers have become the first to link the cumulative effects of single nucleotide polymorphisms (SNP) in genes responsible for the production of oestrogen, to a woman's risk of developing common breast and uterine cancers....
14 June 2010 - by MacKenna Roberts 
The Australian Federal Court in Sydney is considering groundbreaking legal action of whether private companies can obtain patents on human genes....
7 June 2010 - by Dr Tamara Hirsch 
Women who inherit genes linked to breast cancer have no greater risk than other women of developing the disease as a result of lifestyle choices, including hormone replacement therapy (HRT) and alcohol consumption, according to a recent study in The Lancet....
18 October 2009 - by Rosie Beauchamp 
A research team led by Professor Gareth Evans at theNightingale Centre and Genesis Prevention Centre based in the Wythenshawe Hospital in Greater Manchester, UK, will carry out the biggest ever study to look at the causes of breast cancer with the aim of improving screening and diagnosis. One in 10 women in the UK develop breast cancer with 44,000 diagnoses a year, making it the most common cancer in British women....
29 June 2009 - by Dr Rebecca Robey 
A new drug for the treatment of inherited forms of breast, ovarian and prostate cancer has shown promising results in early clinical trials. The study, published in the New England Journal of Medicine, reported that the drug promoted tumour reduction and clinical improvement in advanced-stage cancer patients whilst causing fewer side effects than conventional chemotherapy....
to add a Comment.

By posting a comment you agree to abide by the BioNews terms and conditions

Syndicate this story - click here to enquire about using this story.